Press Release
Press Release
Press Contacts: Erik Cummins, Matt Hyams, Taina Rosa, Olivia Thomas
01.03.25
Pillsbury advised Shanghai-based biopharmaceutical company Henlius in its strategic collaboration with AL-TIRYAQ AL-KHALAWI Medical Company (SVAX), a subsidiary of Saudi Arabia's Fakeeh family business group.
The two parties will establish joint ventures in Saudi Arabia to integrate Henlius’ leading capabilities in the research, development, and manufacturing of biologics with SVAX's local expertise in registration, market access, and commercialization. The collaboration seeks to advance the global registration and commercialization of multiple Henlius products and enhance the accessibility of advanced biologics across the Middle East, North Africa, and Turkey (MENAT).
In addition, the two parties will jointly invest in the development of Henlius’s investigational biosimilar of pembrolizumab, HLX17, to accelerate its global registration and commercialization.
To learn more about the transaction, click here.
The Pillsbury deal team was led by Corporate partners Jia Yan in Shanghai, James Campbell in London and Intellectual Property partner David Tsai in San Fransico, and included Corporate counsel Devin Geng, Mergers & Acquisitions associate Yanqiu Liu in Shanghai, Intellectual Property associate John Steger in San Francisco and Khalid Al-Arfaj in Saudi Arabia.